To investigate the antitumor effect of a combination of knockdown of Tug1 with the use of a Pdl1 monoclonal antibody, orthotopic HCC mouse models were randomly divided into 4 groups and treated with IgG plus NC‐siRNAs, anti‐Pdl1 plus NC‐siRNAs, IgG plus Tug1‐siRNAs, or anti‐Pdl1 plus Tug1‐siRNAs separately (Figure 7G). Here, TUG1 is linked to hepatocellular carcinoma.